Cited by 896Fatty Acid Research and HealthSchizophrenia research and treatmentBipolar Disorder and Treatment

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial

Open access

Amminger, G. Paul, Schäfer, Miriam R., Papageorgiou, Konstantinos, Klier, Claudia M., Cotton, Sue M., Harrigan, Susan M., Mackinnon, Andrew, McGorry, Patrick D., Berger, Gregor E.·2010·Archives of General Psychiatry

DOI 10.1001/archgenpsychiatry.2009.192

Open this paper in CoChat — free account Open PDF

Abstract

CONTEXT: The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation. OBJECTIVE: To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis. DESIGN: Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007. SETTING: Psychosis detection unit of a large public hospital in Vienna, Austria. PARTICIPANTS: Eighty-one individuals at ultra-high risk of psychotic disorder. INTERVENTIONS: A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months. MAIN OUTCOME MEASURES: The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition. RESULTS: Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups. CONCLUSIONS: Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states. Trial Registration clinicaltrials.gov Identifier: NCT00396643.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archgenpsychiatry.2009.192

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder
van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. (2009) · Psychological Medicine · doi:10.1017/s0033291708003814 · Cited by 2,343
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
The Family History Method Using Diagnostic Criteria
Andreasen, N. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770220111013 · Cited by 1,903
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595

Show all 45 references

Research works printed but not linked: 1

First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.

Sorted by citations

Items 501–600 of 895

Psychiatric Disorders in Medical Practice
Lyness, J. M. (2012) · Goldman's Cecil Medicine · doi:10.1016/b978-1-4377-1604-7.00404-8 · Cited by 12
Omega-3 and Omega-6 fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort
Thompson, A. D., Jones, H. J., Heron, J., Hibbeln, J. R., Sullivan, S. A., & Zammit, S. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.09.018 · Cited by 15
[Retracted] Effects of Omega‐3 Polyunsaturated Fatty Acids on Cognitive Function after Splenectomy in Rats
Guo, Y., Feng, P., Cao, Y., Shang, J., Zhang, J., Jiang, H., & Fang, S. (2021) · BioMed Research International · doi:10.1155/2021/5513886 · Cited by 13
Retracted
Prediction and prevention of the first psychotic episode: new directions and opportunities
Marchese, G., Piras, S., Casu, G., Casu, M. A., Orrù, A., Ruiu, S., Pilleri, A., & Manca, G. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s55770 · Cited by 13
Prodromes and Preclinical Detection of Brain Diseases: Surveying the Ethical Landscape of Predicting Brain Health
Ahlgrim, N. S., Garza, K. M., Hoffman, C. A., & Rommelfanger, K. S. (2019) · eNeuro · doi:10.1523/eneuro.0439-18.2019 · Cited by 16
Criticism of the DSM-V risk syndrome: A rebuttal
Carpenter, W. T. (2011) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2011.554278 · Cited by 12
Subtypes of Clinical High Risk for Psychosis that Predict Antipsychotic Effectiveness in Long-Term Remission
Zhang, T., Wang, J., Xu, L., Wei, Y., Tang, X., Hu, Y., Cui, H., Tang, Y., Hui, L., Li, C., et al. (2020) · Pharmacopsychiatry · doi:10.1055/a-1252-2942 · Cited by 13
Shared Decision Making With Young People at Ultra High Risk of Psychotic Disorder
Simmons, M. B., Brushe, M. E., Elmes, A., Polari, A. R., Nelson, B., & Montague, A. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.683775 · Cited by 12
Plasma biomarkers in adolescents with schizophrenia‐spectrum disorder
Zakowicz, P. T., Skibińska, M., Waśniewski, F., Skulimowski, B., & Pawlak, J. (2023) · Early Intervention in Psychiatry · doi:10.1111/eip.13414 · Cited by 12
Prevention of Schizophrenia--Will a Broader Prevention Agenda Support This Aim?
Jacka, F. N., & Berk, M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt202 · Cited by 12
Comments on Bozzatello et al. Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. J. Clin. Med. 2016, 5, 67
Berger, G. E. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5080069 · Cited by 13
Self-citation
Niacin skin flush and membrane polyunsaturated fatty acids in schizophrenia from the acute state to partial remission: a dynamic relationship
Yu, Y., Su, H., Lin, S., Hsiao, P., Lin, Y., Liu, C., Hwang, T., Hsieh, M. H., Liu, C., Chien, Y., et al. (2022) · Schizophrenia · doi:10.1038/s41537-022-00252-w · Cited by 12
Niacin Skin Flush Backs—From the Roots of the Test to Nowadays Hope
Sitarz, R., Juchnowicz, D., Karakuła, K. H., Forma, A., Baj, J., Róg, J., Karpiński, R., Machrowska, A., & Karakuła‐Juchnowicz, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051879 · Cited by 12
Assessment of causal relationships between omega-3 and omega-6 polyunsaturated fatty acids in bipolar disorder: a 2-sample bidirectional mendelian randomization study
Zhang, M., Li, X., Dong, L., Jin, M., Xie, M., Jia, N., Liu, Y., Xue, F., Li, W., Yang, Y., et al. (2023) · Food & Function · doi:10.1039/d3fo00265a · Cited by 12
Network Meta-Analysis Indicates Superior Effects of Omega-3 Polyunsaturated Fatty Acids in Preventing the Transition to Psychosis in Individuals at Clinical High-Risk
Chen, C., Deng, Y., Li, Y., Zhang, M., Yu, T., Xie, K., Bao, W., Li, P., Sun, L., Zhang, T., et al. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae014 · Cited by 12
Assessing adolescent preference in the treatment of first‐episode psychosis and psychosis risk
Welsh, P., & Tiffin, P. A. (2013) · Early Intervention in Psychiatry · doi:10.1111/eip.12077 · Cited by 12
Childhood trauma and distress experiences associate with psychotic symptoms in patients attending primary and psychiatric outpatient care. Results of the RADEP study
Luutonen, S. H., Tikka, M., Karlsson, H., & Salokangas, R. K. R. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.005 · Cited by 12
Working With Asian American Youth at Clinical High Risk for Psychosis
Li, H., Friedman‐Yakoobian, M. S., Min, G., Gnong-Granato, A., & Seidman, L. J. (2013) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e3182948084 · Cited by 12
Preventing Schizophrenia and Severe Mental Illness
DeVylder, J. (2015) · Research on Social Work Practice · doi:10.1177/1049731515622687 · Cited by 15
Pro-Inflammatory Cytokines in Psychiatric Disorders in Children and Adolescents: A Review
Miłkowska, P., Popko, K., Demkow, U. A., & Wolańczyk, T. (2017) · Advances in experimental medicine and biology · doi:10.1007/5584_2017_24 · Cited by 12
Assessment of Risk for Psychosis
Shapiro, D. I., Li, H., Kline, E. R., & Niznikiewicz, M. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-17336-4_2 · Cited by 13
The Antipsychotic Effects of Omega-3 Fatty Acids in Rats
Kokaçya, M. H., Çöpoğlu, Ü. S., Dokuyucu, R., İnanır, S., & Erbaş, O. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000531 · Cited by 13
Omega-3 fatty acids in cause, prevention and management of violence in schizophrenia: Conceptualization and application
Ouyang, W., Sun, G., & Hsu, M. (2019) · Aggression and Violent Behavior · doi:10.1016/j.avb.2019.101347 · Cited by 12
Duration of untreated psychosis : association with clinical and social outcomes and brain morphology in schizophrenia
Penttilä, M. (2013) · Cited by 11
Review: Efficacy of preventative interventions for children and adolescents at clinical high risk of psychosis – a systematic review and meta‐analysis of intervention studies
Frearson, G., Olivares, J. D. O., Catalán, A., Aymerich, C., & de Pablo, G. S. (2024) · Child and Adolescent Mental Health · doi:10.1111/camh.12755 · Cited by 10
Human Brain Myelination Trajectories Across the Life Span
Sherin, J. E., & Bartzokis, G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-378638-8.00015-4 · Cited by 11
Association Between Vitamin D Status and Schizophrenia
Salavert, J., Grados, D., Ramiro, N., Carrión, M. I. H., Fadeuilhe, C., Palma-Álvarez, R. F., López, L. S., Erra, A., & Ramírez, N. (2017) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000670 · Cited by 11
The critical periods of cerebral plasticity: A key aspect in a dialog between psychoanalysis and neuroscience centered on the psychopathology of schizophrenia
The, J. T., Magistretti, P. J., & Ansermet, F. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1057539 · Cited by 14
The Next Big Thing in Child and Adolescent Psychiatry
Shoemaker, E. Z., Tully, L. M., Niendam, T. A., & Peterson, B. S. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.05.010 · Cited by 12
Negative Prognostic Effect of Baseline Antipsychotic Exposure in Clinical High Risk for Psychosis (CHR-P): Is Pre-Test Risk Enrichment the Hidden Culprit?
Raballo, A., Poletti, M., & Preti, A. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab030 · Cited by 11
Meta-analysis of medical and non-medical treatments of the prodromal phase of psychotic illness in at-risk mental states.
Kelly, C. J., Hadjinicolaou, A. V., Holt, C., Agius, M. A., & Zaman, R. (2010) · PubMed · Cited by 11
Predictors of longer-term outcome in the Vienna omega-3 high-risk study
Mossaheb, N., Schäfer, M. R., Schlögelhofer, M., Klier, C. M., Smesny, S., McGorry, P. D., Berger, M., & Amminger, G. P. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.08.010 · Cited by 11
Self-citation
Baseline data of a sequential multiple assignment randomized trial (STEP study)
Hartmann, J., Nelson, B., Amminger, G. P., Spark, J., Yuen, H. P., Kerr, M., Polari, A. R., Wallis, N., Blasioli, J., Dixon, L. B., et al. (2022) · Early Intervention in Psychiatry · doi:10.1111/eip.13263 · Cited by 10
Self-citation
Nutrition and schizophrenia: associations worthy of continued revaluation
Tang, M., Zhao, T., Liu, T. C., Dang, R., Cai, H., & Wang, Y. (2023) · Nutritional Neuroscience · doi:10.1080/1028415x.2023.2233176 · Cited by 10
The therapeutic effect of omega-3 polyunsaturated fatty acids on symptom severity of psychosis: A systematic review and meta-analysis
Rossier, A. T., & Hallahan, B. P. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1804 · Cited by 10
Ethical Implications for Clinical Practice and Future Research in “At Risk” Individuals
Singh, F., Mirzakhanian, H., Fusar‐Poli, P., de la Fuente‐Sandoval, C., & Cadenhead, K. S. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316262 · Cited by 10
Combined individual and family therapy in comparison to treatment as usual for people at‐risk of psychosis: A feasibility study (IF CBT): Trial rationale, methodology and baseline characteristics
Law, H., Izon, E., Au‐Yeung, K., Morrison, A. P., Byrne, R. E., Notley, C. J., Yung, A. R., Norrie, J. D., & French, P. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12922 · Cited by 10
Overdiagnosis, Underdiagnosis, Synthesis: A Dialectic for Psychiatry and the DSM
Pierre, J. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6504-1_8 · Cited by 10
Affect recognition and functioning in putatively prodromal individuals
Amminger, G. P., Allott, K., Schlögelhofer, M., Thompson, A. D., Bechdolf, A., Nelson, B., Mossaheb, N., & Schäfer, M. R. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.04.008 · Cited by 10
Self-citation
No effect of oral tyrosine on total tyrosine levels in breast milk: implications for dietary supplementation in early postpartum
Dowlati, Y., Ravindran, A. V., Maheux, M., Steiner, M. S., Stewart, D. E., & Meyer, J. H. (2014) · Archives of Women s Mental Health · doi:10.1007/s00737-014-0441-8 · Cited by 10
A Structure-Function Mechanism for Schizophrenia
Vadakkan, K. I. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00108 · Cited by 10
Treatment possibilities for individuals at clinical high risk of psychosis
Brummitt, K., & Addington, J. (2012) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2012.00370.x · Cited by 10
Jung's views on causes and treatments of schizophrenia in light of current trends in cognitive neuroscience and psychotherapy research I. Aetiology and phenomenology
Silverstein, S. M. (2014) · Journal of Analytical Psychology · doi:10.1111/1468-5922.12057 · Cited by 11
Early intervention in psychosis: Still the ‘best buy’?
Castle, D. J., & Singh, S. P. (2015) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.114.160630 · Cited by 10
ω-3 Polyunsaturated Fatty Acids to Prevent Psychosis
Kane, J. M., & Correll, C. U. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2945 · Cited by 10
Early psychotic experiences: Interventions, problems and perspectives.
Dimitrakopoulos, S., Kollias, C. T., Stefanis, N. C., & Kontaxakis, V. P. (2015) · PubMed · Cited by 10
Longitudinal Trajectories of Plasma Polyunsaturated Fatty Acids and Associations With Psychosis Spectrum Outcomes in Early Adulthood
Mongan, D., Perry, B. I., Healy, C., Susai, S. R., Zammit, S., Cannon, M. D., & Cotter, D. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.04.004 · Cited by 9
Advancements and Future Directions in Prevention Based on Evaluation for Individuals With Clinical High Risk of Psychosis: Insights From the SHARP Study
Zhang, T., Xu, L., Wei, Y., Cui, H., Tang, X., Hu, Y., Tang, Y., Wang, Z., Liu, H., Chen, T., et al. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae066 · Cited by 12
Preventing disease progression in schizophrenia: What are we waiting for
Lieberman, J. A., Mendelsohn, A. I., Goldberg, T. E., & Emsley, R. A. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.12.042 · Cited by 9
Risk, Disorder and Diagnosis
Yung, A. R. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.614926 · Cited by 9
Analysis of polyunsaturated fatty acids in antipsychotic-free individuals with at-risk mental state and patients with first-episode schizophrenia
Le, A. T. P., Higuchi, Y., Sumiyoshi, T., Itoh, H., Sasabayashi, D., Takahashi, T., & Suzuki, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1188452 · Cited by 11
Suboptimal dietary quality is associated with mental symptoms among adults aged 40 years and over in China: A population-based cross-sectional study
Ma, S., Zhu, J. L., Xie, S., Chen, R., Li, X., & Wei, W. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.071 · Cited by 9
Predicting clinical response in people at ultra-high risk of psychosis: a systematic and quantitative review
Mechelli, A., Prata, D. P., Kefford, C., & Kapur, S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.03.003 · Cited by 9
The 3rd Schizophrenia International Research Society Conference, 14–18 April 2012, Florence, Italy: Summaries of oral sessions
Abbs, B., Achalia, R. M., Adelufosi, A. O., Aktener, A. Y., Beveridge, N. J., Bhakta, S. G., Blackman, R. K., Bora, E., Byun, M. S., Cabanis, M., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.07.024 · Cited by 8
Neuroprogression in schizophrenia: Pathways and underpinning clinical staging and therapeutic corollaries
Stein, K., & Broome, M. R. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414556321 · Cited by 9
Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia
Buchanan, R. W., Weiner, E., Kelly, D. L., Gold, J. M., Chen, S., Zaranski, J., Blatt, F., Wehring, H. J., & Carpenter, W. T. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001253 · Cited by 9
A Systematic Review of Effectiveness of Omega-3 Fatty Acid Supplementation on Symptoms, Social Functions, and Neurobiological Variables in Schizophrenia
Hsu, M., & Ouyang, W. (2021) · Biological Research For Nursing · doi:10.1177/10998004211020121 · Cited by 9
Epigenetics and first-episode psychosis: A systematic review
Lockwood, L. E., Miller, B. J., & Youssef, N. A. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114325 · Cited by 9
Machine learning based prediction and the influence of complement – Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial
Susai, S. R., Mongan, D., Healy, C., Cannon, M. D., Cagney, G., Wynne, K. J., Byrne, J. F., Markulev, C., Schäfer, M. R., Berger, M., et al. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.03.013 · Cited by 9
Self-citation
Interventions for Youth at Risk of Bipolar Disorder
Duffy, A. C. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-013-0006-x · Cited by 9
Young Rural People at Risk for Schizophrenia: Time for Mental Health Services to Translate Research Evidence into Best Practice of Care
Stain, H. J., Clark, S. C., O׳Donnell, M., & Schall, U. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2010.493857 · Cited by 9
Schizophrenia and psychosis
Hollis, C. P., & Palaniyappan, L. K. (2015) · Wiley eBooks · doi:10.1002/9781118381953.ch57 · Cited by 9
Psychosis risk syndrome excluded from DSM-5
Maxmen, A. (2012) · Nature · doi:10.1038/nature.2012.10610 · Cited by 9
The psychosis continuum: Systematic review on prodromal markers, symptom progression, and early intervention strategies
Ricci, V., Sarni, A., Martinotti, G., & Maina, G. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104725 · Cited by 10
Is it possible to prevent excessive synaptic pruning in schizophrenia? Possibilities and limitations
Pawlak, A., Stefanowicz, J., Kotkowska, Z., Gabryelska, A., Sochal, M., Napieraj, F., Kotlicka‐Antczak, M., & Strzelecki, D. (2025) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2025.1656232 · Cited by 9
Physical Health and Transition to Psychosis in People at Clinical High Risk
Micheli, A. D., Provenzani, U., Krakowski, K., Oliver, D., Damiani, S., Brondino, N., McGuire, P. K., & Fusar‐Poli, P. (2024) · Biomedicines · doi:10.3390/biomedicines12030523 · Cited by 8
Impacts of Omega-3 Fatty Acids, Natural Elixirs for Neuronal Health, on Brain Development and Functions
Rao, A. S., Nair, A., Nivetha, K., Bibi, A., Kapadia, H., Vora, D., Veena, S. M., Anantharaju, K. S., & More, S. S. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3662-6_15 · Cited by 10
Adolescents and young adults at ultrahigh risk of psychosis: detection, prediction and treatment. A review of current knowledge.
Mees, L., Zdanowicz, N., Reynaert, C., & Jacques, D. (2011) · PubMed · Cited by 8
Behavioural effects of high fat diet in a mutant mouse model for the schizophrenia risk gene neuregulin 1
Holm‐Hansen, S., Low, J. K., Zieba, J., GJEDDE, A. H., Bergersen, L. H., & Karl, T. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12267 · Cited by 8
Pharmacological and Nonpharmacological Interventions to Arrest Neuroprogression in Psychiatric Disorders
Boufidou, F., & Halaris, A. E. (2017) · Modern trends in psychiatry · doi:10.1159/000470814 · Cited by 9
Re-inventing the schizophrenia syndrome: The elusive “theory of everything”
Nasrallah, H. A. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.11.006 · Cited by 8
Prodromes de la schizophrénie : consensus ou confusion ?
Teyssier, J. (2013) · L Encéphale · doi:10.1016/j.encep.2012.11.002 · Cited by 8
Psychoedukation bei Personen mit erhöhtem Psychoserisiko
Zarafonitis, S., Wagner, M., Pützfeld, V., Berning, J., Janssen, B., Decker, P., Ronald Bottlender, A., Möller, H., Gäebel, W., Maier, W., et al. (2012) · Psychotherapeut · doi:10.1007/s00278-012-0928-6 · Cited by 8
Indicated prevention with long‐chain polyunsaturated omega‐3 fatty acids in patients with 22q11 DS genetically at high risk for psychosis. Protocol of a randomized, double‐blind, placebo‐controlled treatment trial
Armando, M., Crescenzo, F. D., Vicari, S., Digilio, M. C., Pontillo, M., Papaleo, F., & Amminger, G. P. (2014) · Early Intervention in Psychiatry · doi:10.1111/eip.12197 · Cited by 8
Self-citation
The Prevention of Mental Disorders has a Bright Future
Ajdacic‐Gross, V. (2014) · Frontiers in Public Health · doi:10.3389/fpubh.2014.00060 · Cited by 9
Lipides membranaires dans la schizophrénie et la psychose débutante : de potentiels biomarqueurs et pistes thérapeutiques ?
Frajerman, A., Kébir, O., Chaumette, B., Tessier, C., Lamazière, A., Nuss, P., & Krebs, M. (2020) · L Encéphale · doi:10.1016/j.encep.2019.11.009 · Cited by 9
Influence of olive oil–based nanoemulsion on the fatty acid profiles of rainbow trout fillets
Durmuş, M., Bensid, A., Özoğul, Y., Köşker, A. R., Uçar, Y., Küley, E., Durmuş, M., & Özoğul, F. (2020) · Aquaculture International · doi:10.1007/s10499-020-00574-5 · Cited by 8
‘Prodromal Diagnosis’ of Psychosis: An Impartial Commentary
Jorm, A. F. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.585132 · Cited by 8
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
N-3 Fatty Acids for Hypertriglyceridemia in Patients Taking Second-Generation Antipsychotics
Fetter, J. C., Brunette, M., & Green, A. I. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.febr.012513 · Cited by 7
Effectiveness of Omega-3 Fatty Acids Versus Placebo in Subjects at Ultra-High Risk for Psychosis: The PURPOSE Randomized Clinical Trial
Rossum, I. W.-V., Slot, M. I. E., van Hell, H. H., Bossong, M. G., Berger, G. E., Aschauer, H. N., Maat, A., Walitza, S., Lavan, O., Baeza, I., et al. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae186 · Cited by 7
Self-citation
Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Bumb, J. M., Enning, F., & Leweke, F. M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660165 · Cited by 7
A Dialogue About the U.S. Dialogue on Mental Health: Exploring the Nature, Scope, and Implications of the Conversation
Hess, J. Z., Decker, A., Lacasse, J. R., & Foster, M. (2016) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.18.3.172 · Cited by 7
Staging Models and Functional Outcomes in Bipolar Disorder: Clinical Implications
Passos, I. C., Kapczinski, N. S., Quevedo, J., Kauer‐Sant’Anna, M., & Kapczinski, F. P. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0046-5 · Cited by 7
Controversies in Psychiatry and DSM-5: The Relevance for Social Work (Occasional Essay)
Littrell, J. L., & Lacasse, J. R. (2012) · Families in Society The Journal of Contemporary Social Services · doi:10.1606/1044-3894.4236 · Cited by 7
Early interventions for prodromal stage of psychosis
Bošnjak, D., Kekin, I., Hew, J., & Kuzman, M. R. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012236 · Cited by 7
At-risk mental states
Yung, A. (2020) · Risk Factors for Psychosis · doi:10.1016/b978-0-12-813201-2.00003-x · Cited by 2
Schizotypy and help‐seeking for anxiety
Blanch, S., & Barkus, E. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.13079 · Cited by 7
Brain Derived Neurotrophic Factor Deficiency is Associated with Cognitive Impairment and Elevated Phospholipase A2 Activity in Plasma of Mice
Schmidt, M., Rossetti, A. C., Brandwein, C., Riva, M. A., Gass, P., Elsner, P. U., Hesse, J., Hipler, U., Smesny, S., & Milleit, B. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.11.024 · Cited by 7
Diet and Mental Health: An Up-to-Date Analysis
Casper, R. C. (2011) · World review of nutrition and dietetics · doi:10.1159/000327798 · Cited by 7
Attitudes of patients and clinicians in relation to the at‐risk state for psychosis
Welsh, P., & Tiffin, P. A. (2013) · Early Intervention in Psychiatry · doi:10.1111/eip.12062 · Cited by 7
Is clinical intervention in the ultra high risk phase effective?
McGuire, P. K., Selvaraj, S., & Howes, O. D. (2011) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462011000600004 · Cited by 7
Correlates of electroencephalographic resting states and erythrocyte membrane docosahexaenoic and eicosapentaenoic acid levels in individuals at ultra-high risk of psychosis
Lavoie, S., Whitford, T. J., Benninger, F., Feucht, M., Kim, S., Klier, C. M., McNamara, R. K., Rice, S., Schäfer, M. R., & Amminger, G. P. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415571168 · Cited by 7
Self-citation
Does early diagnosis and treatment of schizophrenia lead to improved long-term outcomes?
Agius, M. A., Butler, S., & Holt, C. (2011) · Neuropsychiatry · doi:10.2217/npy.11.71 · Cited by 7
The Psychoses in DSM-5 and in the Near Future
Carpenter, W. T. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020207 · Cited by 7
Fatty acids and schizophrenia
Peet, M., & Williamson, K. (2011) · Elsevier eBooks · doi:10.1533/9780857092922.3.464 · Cited by 7
Conceptualizing Schizophrenia Through Attenuated Symptoms in the Population
Carpenter, W. T. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060854 · Cited by 7
Lipids in the Treatment of Mental Disorders
Lange, K. W. (2020) · Wiley eBooks · doi:10.1002/047167849x.bio120 · Cited by 7
A closer look at the role of nutrition in children and adults with ADHD and neurodivergence
Hunter, C., Smith, C., Davies, E., Dyall, S. C., & Gow, R. V. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1586925 · Cited by 9
Modulation of ceramides through nutrition: A new target in obesity and insulin resistance (Narrative Review)
Arias-Marroquín, A. T., Torre-Villalvazo, I., Granados‐Portillo, O., Villegas-Romero, M., Camacho‐Morales, A., Tovar-Palacios, A., Aguilar-Salinas, C. A., Illescas-Zárate, D., & Vázquez-Manjarrez, N. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.11.156 · Cited by 6

Authors: Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E.
Affiliations: Medical University of Vienna (AT)
The University of Melbourne (AU)
Clienia AG (CH)
ORCID: Amminger, G. Paul
Papageorgiou, Konstantinos
Klier, Claudia M.
Cotton, Sue M.
Mackinnon, Andrew
McGorry, Patrick D.
Berger, Gregor E.
Venue: Archives of General Psychiatry
Publisher: American Medical Association (AMA)
Published: 2010-02-01
Volume: 67
Issue: 2
Pages: 146
ISSN: 0003-990X (ISSN-L)
DOI: 10.1001/archgenpsychiatry.2009.192
OpenAlex: W2130372506
Cited by: 896
References: 45
Citations by year: 2026: 13 · 2025: 20 · 2024: 29 · 2023: 22 · 2022: 20 · 2021: 51 · 2020: 42 · 2019: 59 · 2018: 33 · 2017: 52 · 2016: 69 · 2015: 82 · 2014: 95 · 2013: 85 · 2012: 98
FWCI: 92.57
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Archives of General Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: Stanley Medical Research Institute (03T-315)
Topics: Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: omega-3 polyunsaturated fatty acids, clinical high risk for psychosis, schizophrenia, adolescents and young adults, n-6/n-3 ratio, erythrocyte fatty acids, positive symptoms, negative symptoms, functional outcome, dietary supplementation, psychosis prevention, omega-3 deficiency
MeSH terms: Adolescent, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Female, Health Status, Humans, Male, Patient Acceptance of Health Care, Psychotic Disorders, Risk Factors, Schizotypal Personality Disorder, Severity of Illness Index, Fatty Acids, Omega-3, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks